Publications by authors named "F Spyratos"

Claim this Profile
Expression Is Predictive of Response to Neoadjuvant Celecoxib in -negative Breast Cancer Patients.
Patricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, Véronique Scott, Brigitte Sigal, Frédérique Spyratos

Anticancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
A S Hamy, I Bieche, J Lehmann-Che, V Scott, Ph Bertheau, F Spyratos

Breast Cancer Res Treat· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.
F Valet, P de Cremoux, F Spyratos, N Servant, M E Dujaric

Breast· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Magdalena Cizkova, Sophie Vacher, Didier Meseure, Martine Trassard, Aurélie Susini, Frederique Spyratos

BMC Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
Jocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, Marie-Joëlle Mozziconacci, Martine Antoine

BMC Cancer· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis